Submitted for Publication: February 18, 2013; final revision received May 27, 2013; accepted July 2, 2013.
Study concept and design: Teknos, Old, Agrawal.
Acquisition of data: Hall, Byrum, Teknos, Old, Agrawal.
Analysis and interpretation of data: Marcinow, Hall, Teknos, Old, Agrawal.
Drafting of the manuscript: Marcinow, Hall, Agrawal.
Critical revision of the manuscript for important intellectual content: Hall, Byrum, Teknos, Old, Agrawal.
Statistical analysis: Marcinow, Byrum, Agrawal.
Administrative, technical, or material support: Hall, Teknos, Old, Agrawal.
Study supervision: Hall, Teknos, Old, Agrawal.
Conflict of Interest Disclosures: None reported.
Funding/Support: The data from the present study derive in part from multi-institutional trial NEO3-06 sponsored by Navidea Biopharmaceuticals Inc (Dublin, Ohio).
Role of the Sponsor: Navidea Biopharmaceuticals provided no funding for this article. The authors have no relevant financial or other relationship with Navidea Biopharmaceuticals.
Previous Presentation: This study was presented at the American Head and Neck Society Eighth International Conference on Head and Neck Cancer; July 23, 2012; Toronto, Ontario, Canada.
Additional Contributions: Navidea Biopharmaceuticals provided the use of a model 2100 intraoperative radioisotope detector.
Additional Information:99mTc–tilmanocept is a registered trademark of Navidea Biopharmaceuticals.